• Thanks for stopping by. Logging in to a registered account will remove all generic ads. Please reach out with any questions or concerns.

Trump administration 2024-2028

So 90 day pause on tariffs for everyone while dealing with China who called their bluff.

125% on China now.
 
So 90 day pause on tariffs for everyone while dealing with China who called their bluff.

125% on China now.

He blinked. China’s still gonna be a problem, but between the bond markets, what was gonna happen with freight logjammed in ports, and the market collapse, someone must have finally gotten some sense through to him.
 
He blinked. China’s still gonna be a problem, but between the bond markets, what was gonna happen with freight logjammed in ports, and the market collapse, someone must have finally gotten some sense through to him.

Live camera from the White House right now:

burning homer simpson GIF
 
So 90 day pause on tariffs for everyone while dealing with China who called their bluff.

125% on China now.
But we are still looking at our 25% on steel and aluminum and 10% on energy - correct?
So the Orange man lumps us in with China and Mexico still. If this is correct, it says alot to me as to our continued need to re-focus our attention/resources/skills to expanding our trade and relationships with others outside of the US.
 
So one of the biggest limfacs for the US economy is access to Active Pharmaceutical Ingredients...

Companies in India, China, and Europe continue to play an outsized role in manufacturing active pharmaceutical ingredients (API) used in products destined for the US market in terms of locations cited in API drug master files (DMFs) filed with the US Food and Drug Administration (FDA).

According to the US Pharmacopeia’s (USP) Medicine Supply Map, only 4% of the active API DMFs filed with FDA in 2023 cited US manufacturing facilities; 50% were held by India, followed by China at 32%, the EU at 10% and other countries at 4%. DMFs are submitted to FDA by companies supplying drug ingredients to another company and are confidential and stripped of proprietary information. USP notes that not all drug products are made with APIs referencing DMFs, and that the proportion of DMFs is not necessarily indicative of total output by a country or region.
USP: India and China continue their API manufacturing reign
Yet another short-sighted own goal....
 
He blinked. China’s still gonna be a problem, but between the bond markets, what was gonna happen with freight logjammed in ports, and the market collapse, someone must have finally gotten some sense through to him.
Hard to tell who blinked until the "negotiations" with the 70 or so countries claimed to be seeking them are completed and we find out who conceded what. Will they be negotiating for an agreed higher level of protectionist policies than before, or a lower one?
 
Back
Top